Diagnosing, managing, and preventing salivary gland disorders

Oral Diseases

Volumn 8, Issue 2, 2002, Pages 77-89

  Ship, J A ^a  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

Author keywords

Dry mouth; Medications; Radiotherapy; Saliva; Sj gren's syndrome; Xerostomia

Indexed keywords

ACICLOVIR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIFOSTINE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIPARKINSON AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETHANECHOL; CALCIUM CHANNEL BLOCKING AGENT; CEFALEXIN; CEVIMELINE; CLINDAMYCIN; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; KETOCONAZOLE; OXYBUTYNIN; PILOCARPINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALACICLOVIR;

ACUPUNCTURE; ARTICLE; DENTAL CARIES; DISEASE ASSOCIATION; HUMAN; MOUTH INFECTION; PRIORITY JOURNAL; RADIATION SICKNESS; SALIVARY GLAND DISEASE; SALIVARY GLAND TUMOR; SJOEGREN SYNDROME; XEROSTOMIA;

ADULT; AUTOIMMUNE DISEASES; BIOPSY; CHOLINERGIC AGONISTS; DIAGNOSTIC IMAGING; DISEASE; DRUG THERAPY; HUMANS; ORAL HYGIENE; QUESTIONNAIRES; RADIOTHERAPY; SALIVA; SALIVA, ARTIFICIAL; SALIVARY GLAND DISEASES; SALIVARY GLAND NEOPLASMS; SECRETORY RATE; SJOGREN'S SYNDROME; XEROSTOMIA;

EID: 0036218951     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1601-0825.2002.2o837.x     Document Type: Article

References (163)

1. The growth and morphological behavior of salivary epithelial cells on matrix protein-coated biodegradable substrata
2. Sialadenitis following 1-131 therapy for thyroid carcinoma: Concise communication
3. Oral microbial flora in Sjogren's syndrome
4. Oral microflora in subjects with reduced salivary secretion
5. Submandibular gland mucocele: Diagnosis and management
6. Acupuncture treatment of patients with radiation-induced xerostomia
7. Remaining teeth, oral dryness and dental health habits in middle-aged Norwegian rheumatoid arthritis patients
8. Salivary enhancement: Current status and future therapies
9. Salivary gland dysfunction
10. Salivary gland dysfunction: Causes, symptoms, treatment
11. Complications associated with therapeutic neck radiation
12. Evaluation of stimulated parotid saliva flow rate in different age groups
13. Salivary gland function and aging: A model for studying the interaction of aging and systemic disease
14. Signaling mechanisms that regulate saliva formation
15. Re-engineering the functions of a terminally differentiated epithelial cell in vivo
16. Salivary glands as a model for craniofacial applications of gene transfer
17. Sjogren's syndrome: A critical review of clinical management
18. Low unstimulated salivary flow and subjective oral dryness: Association with medication, anxiety, depression, and stress
19. Sjogren's syndrome. A clinical, pathological, and serological study of sixty-two cases 1965
20. Acupuncture treatment of patients with radiation-induced xerostomia
21. Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment
22. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
23. Radiochemotherapy with amifostine cytoprotection for head and neck cancer
24. Oral colonization by Candida albicans
25. Chemoprotective and radioprotective effects of amifostine: An update of clinical trials
26. Cevimeline (Evoxac) for dry mouth
27. Age-related changes in immunoglobulin isotypes in whole and parotid saliva and serum in healthy individuals
28. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate
29. A longitudinal follow-up of salivary secretion in bone marrow transplant patients
30. Salivary flow and its relation with oral symptoms in terminally ill patients
31. Salivary function and glycemic control in older persons with diabetes
32. A longitudinal analysis of salivary flow in control subjects and older adults with type 2 diabetes
33. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia
34. Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjogren's syndrome
35. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer
36. A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer
37. A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia
38. Circadian rhythms in the flow rate and composition of unstimulated and stimulated human submandibular saliva
39. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man
40. Effects of nine different chewing-gums and lozenges on salivary flow rate and pH
41. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer
42. Oral complications associated with immunosuppression and cancer therapies
43. Oropharyngeal candidiasis: A review of its clinical spectrum and current therapies
44. A clinical comparative trial of saliva substitutes in radiation-induced salivary gland hypofunction
45. A clinical trial of bethanechol in patients with xerostomia after radiation therapy
46. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: Techniques and early results
47. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: Assessment of target coverage and noninvolved tissue sparing
48. Conformal and intensity modulated irradiation of head and neck cancer: The potential for improved target irradiation, salivary gland function, and quality of life
49. Partial irradiation of the parotid gland
50. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer
51. The unique oral health needs of an aging population
52. The establishment of a xerostomia clinic: A prospective study
53. The effect of dehydration on parotid salivary gland function
54. Management of dry mouth
55. Acquired salivary dysfunction
56. Sjogren's syndrome: Current therapies remain inadequate for a common disease
57. Xerostomia: Evaluation of a symptom with increasing significance
58. Subjective reports of xerostomia and objective measures of salivary gland performance
59. Prednisone and piroxicam for treatment of primary Sjogren's syndrome
60. Treatment of primary Sjogren's syndrome with hydroxychloroquine: A retrospective, open-label study
61. Update in Sjogren syndrome
62. Determination of variation of stimulated salivary flow rates
63. The role of salivary function on oropharyngeal colonization
64. Malignant mixed tumors of the salivary glands: A review
65. Oral mucosal biopsy procedures
66. Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma
67. Salivary sIgA concentrations and stimulated whole saliva flow rates among women undergoing chemotherapy for breast cancer: An exploratory study
68. Unstimulated and stimulated parotid salivary flow rate in individuals of different ages
69. Two-year longitudinal study of parotid salivary flow rates in head and neck cancer patients receiving unilateral neck parotid-sparing radiotherapy treatment
70. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy
71. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva
72. A multicenter maintenance Study of oral pilocarpine tablets for radiation-induced xerostomia
73. Donepezil for psychotropic-induced memory loss
74. The efficacy of xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer: A pilot-Study
75. Salivary secretion: Stimulatory effects of chewing-gum versus paraffin tablets
76. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer
77. Chemotherapy for salivary gland cancer
78. Increased risk of lymphoma in sicca syndrome
79. Salivary gland 99mTc-scintigraphy: A grading scale and correlation with major salivary gland flow rates
80. Hydroxychloroquine treatment for primary Sjogren's syndrome: A two year double blind crossover trial
81. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression
82. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients
83. Subjective reports of oral dryness in an older adult population
84. Xerostomia, xerogenic medications and food avoidances in selected geriatric groups
85. A clinicopathologic study of 196 intraoral minor salivary gland tumours
86. Noninvasive scintigraphic method to quantify unstimulated secretions from individual salivary glands
87. Sialochemistry in diseases and clinical situations affecting salivary glands
88. The role of saliva in maintaining oral homeostasis
89. Tumors of salivary glands. Review of 479 cases with particular reference to histological types, site, age and sex distribution
90. Five-year follow-up of saliva in patients treated for lymphomas
91. Five-year follow-up study of saliva, mutans streptococci, lactobacilli and yeast counts in lymphoma patients
92. Saliva in non-insulin-dependent diabetic patients and control subjects: The role of the autonomic nervous system
93. Use of an intra-oral model to evaluate 0.05% sodium fluoride mouth rinse in radiation-induced hyposalivation
94. Tumors of the major and minor salivary glands: Review of 25 years of experience
95. Prevalence of subjective feelings of dry mouth in the elderly
96. Clinical criteria for the diagnosis of salivary gland hypofunction
97. Xerostomia: Prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists
98. Effects of the thiazide diuretic bendroflumethiazide on salivary flow rate and composition
99. Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human parotid and submandibular-sublingual salivary secretion
100. Effects of the antihypertensive drug captopril on human salivary secretion rate and composition
101. Radiation-induced hyposalivation and its treatment with oral pilocarpine
102. Unusual conditions of the major and minor salivary glands
103. Rational drug therapy recommendations for the treatment of patients with Sjogren's syndrome
104. Development of a Visual Analogue Scale questionnaire for subjective assessment of salivary dysfunction
105. Salivary flow and composition in elderly patients referred to an acute care geriatric ward
106. The effect of radiation on normal tissues of the head and neck
107. Xerostomic complaints induced by an anti-sialogogue in healthy young vs. older adults
108. Advances in the diagnosis and management of keratoconjunctivitis sicca
109. Recurrent pleomorphic adenoma of the parotid gland: Report of 126 cases and a review of the literature
110. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olmsted County
111. Infections in the cancer patient
112. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome
113. Chewing stimulates secretion of human salivary secretory immunoglobulin A
114. Immunoquantification of human salivary mucins MG1 and MG2 in stimulated whole saliva: Factors influencing mucin levels
115. Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia
116. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjogren's syndrome
117. Oral pilocarpine for radiation-induced xerostomia: Integrated efficacy and safety results from two prospective randomized clinical trials
118. Infections in patients with cancer
119. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses
120. Secretory sialography in diseases of the major salivary glands
121. Does variability in salivary protein concentrations influence oral microbial ecology and oral health?
122. Investigation of xerostomia in patients with rheumatoid arthritis
123. Salivary gland scintigraphy with 99mTc-pertechnetate in Sjogren's syndrome: Relationship to clinicopathologic features of salivary and lacrimal glands
124. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride
125. Xerostomia in Sjogren's syndrome. Evaluation by sequential salivary scintigraphy
126. Sjogren's syndrome: Pathology, oral presentation, and dental management
127. A quantitative study of histological changes in the human parotid gland occurring with adult age
128. Oral health care for the cancer patient
129. Root caries in the older patient: Significance, prevention, and treatment
130. Oropharyngeal candidosis in the older patient
131. Is reduced salivary flow normal in old people?
132. The relationship between dehydration and parotid salivary gland function in young and older healthy adults
133. Normal salivary gland function: How much saliva is enough?
134. Longitudinal analysis of parotid and submandibular salivary flow rates in healthy, different aged adults
135. Xerostomia and the geriatric patient
136. Oral and systemic factors associated with increased levels of human immunodeficiency virus type 1 RNA in saliva
137. Methotrexate in primary Sjogren's syndrome
138. Distant metastasis in adenoid cystic carcinoma of salivary origin
139. A reference guide to drugs and dry mouth - 2nd edition
140. Comparison between saliva stimulants and a saliva substitute in patients with xerostomia and hyposalivation
141. Diagnostic value of sialography with both the conventional and digital subtraction techniques in children with primary and secondary Sjogren's syndrome
142. Stimulated parotid gland salivary flow rates in normotensive, hypertensive, and hydrochlorothiazide-medicated African Americans
143. Clinical trial of a mucin-containing oral spray for treatment of xerostomia in hospice patients
144. Sjogren's syndrome. Autoimmune epithelitis
145. Bacterial colonization of saliva and plaque in the elderly
146. Sjogren's syndrome: A community-based study of prevalence and impact
147. The occurrence of xerostomia and salivary gland hypofunction in a population-based sample of older South Australians
148. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis
149. Major salivary gland function in patients with radiation-induced xerostomia: Flow rates and sialochemistry
150. Aging and saliva: A review of the literature
151. Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: Results of a prospective multicentre study
152. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: A randomized, placebo-controlled, fixed-dose, multicenter trial: P92-01 Study Group
153. Malignant lymphoma in primary Sjogren's syndrome: A multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's syndrome
154. Investigation of the clinical value of total saliva flow rates
155. A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer
156. Chronic sclerosing sialadenitis of the submandibular and parotid glands: A report of a case and review of the literature
157. Cross-sectional and longitudinal analyses of stimulated parotid salivary constituents in healthy different aged subjects
158. A characterization of major salivary gland flow rates in the presence of medications and systemic diseases
159. Prospects for gene-based immunopharmacology in salivary glands
160. Association of salivary flow rates with maximal bite force
161. Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia
162. Prosthodontic considerations for the older patient